Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema once-weekly for adults with overweight or obesity
2023-506929-11-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 22
01
Overview
Phase 3 trial of cagrilintide and semaglutide in Overweight and obesity, sponsored by Novo Nordisk. Primary endpoints: Relative change in body weight and Achievement of at least 5% weight reduction. Started Oct 2022; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on 2023-506929-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506929-11-00.